Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001104659-22-047864
Filing Date
2022-04-20
Accepted
2022-04-20 16:49:24
Documents
9

Document Format Files

Seq Description Document Type Size
1 FORM S-3 tm2212977d1_s3.htm S-3 259224
2 EXHIBIT 4.3 tm2212977d1_ex4-3.htm EX-4.3 377977
3 EXHIBIT 4.4 tm2212977d1_ex4-4.htm EX-4.4 369117
4 EXHIBIT 5.1 tm2212977d1_ex5-1.htm EX-5.1 20334
5 EXHIBIT 23.1 tm2212977d1_ex23-1.htm EX-23.1 3767
6 EX-FILING FEES tm2212977d1_ex-filingfees.htm EX-FILING FEES 54954
7 GRAPHIC tm2212977d1_ex5-1img01.jpg GRAPHIC 12373
8 GRAPHIC tm2212977d1_ex23-1img01.jpg GRAPHIC 2728
9 GRAPHIC tm2212977d1_s3sp1.jpg GRAPHIC 11565
  Complete submission text file 0001104659-22-047864.txt   1123773
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-264394 | Film No.: 22838683
SIC: 2836 Biological Products, (No Diagnostic Substances)